Phosphorus

Canada and the United States release the State of the Great Lakes 2022 Report and the 2022 Progress Report of the Parties showing continuing restoration of the Great Lakes

Retrieved on: 
Monday, August 15, 2022 - 4:00pm
Public forum debate, AOCS, Environment and Climate Change Canada, Risk, Comment, Phosphorus, Lake, Ecosystem, United States Environmental Protection Agency, Drinking water, Silver, Party, Partnership, Illinois River, Climate change, Forum, Nutrient, Science, Progress Report, Agreement, Environment, Health, Oil, Aquaculture, Lake Erie, QC, Great

Today, Environment and Climate Change Canada and the United States Environmental Protection Agency jointly published two reports required under the Agreement: the State of the Great Lakes 2022 Report and the 2022 Progress Report of the Parties.

Key Points: 
  • Today, Environment and Climate Change Canada and the United States Environmental Protection Agency jointly published two reports required under the Agreement: the State of the Great Lakes 2022 Report and the 2022 Progress Report of the Parties.
  • Over 120Great Lakes scientists and other experts worked to assemble available data and prepare Great Lakes assessments.
  • The Progress Report of the Parties describes recent achievements in restoring and protecting Great Lakes water quality and ecosystem health.
  • "Over the past fifty years, the United States and Canada have made tremendous progress working together to protect the Great Lakes and support a thriving regional economy.

GWT and Xylem announced as a finalist winner in Singapore PUB's Carbon Zero Grand Challenge 2022

Retrieved on: 
Thursday, August 11, 2022 - 3:05pm
Carbon, Zero, GWT, Multimedia, RAB, Grand Challenges, Industry, Pub, Phosphorus, Technology, Xylem Inc., Iowa State University, Bacteria, CO2, Partnership, Nitrogen, Water, AD, Solution, XYL, Nitrous oxide, Biofuel, PUB, Entrepreneurship, Renewable energy, Sewage, Xylem

As part of this challenge, PUB sought carbon capture, utilization, removal and other solutions that could be integrated with its operations and reach commercial scale within a decade or sooner.

Key Points: 
  • As part of this challenge, PUB sought carbon capture, utilization, removal and other solutions that could be integrated with its operations and reach commercial scale within a decade or sooner.
  • As a Grand Challenge finalist, the GWT/Xylem project will be awarded up to $2.5 million to demonstrate a large-scale version of their solution at a PUB facility in Singapore.
  • According to GWT President and Co-Founder, Dr. Martin Gross, "Our company is honored to be selected as a finalist in the PUB's Grand Carbon Challenge.
  • Our partnership with Xylem at PUB Singapore will serve as a showcase for how algae treatment can be leveraged to decarbonize the wastewater treatment industry."

Alma, a Sisram Medical Company, Launches the Alma Hybrid® and Alma TED™ Systems in Canada

Retrieved on: 
Thursday, August 11, 2022 - 2:00pm
Company, FDA, Radio frequency, View, Multimedia, CO2, Solution, Patient, Ultrasound, Growth, Phosphorus, Medical device, Plasma, Laser

"Regulatory clearances remain a critical milestone in our North America commercial launch strategy because it strengthens and diversifies our products to include key markets like Canada," said Keith Adams, President of Alma, North America.

Key Points: 
  • "Regulatory clearances remain a critical milestone in our North America commercial launch strategy because it strengthens and diversifies our products to include key markets like Canada," said Keith Adams, President of Alma, North America.
  • "We're excited to offer innovative energy-based solutions and revenue opportunities, like Alma Hybrid and Alma TED, to our providers throughout Canada as we look towards continuing our growth and expanding our footprint into this market."
  • Alma is a global innovator of Laser, Light-based, Radiofrequency, Plasma, and Ultrasound solutions for the aesthetic and surgical markets.
  • We enable practitioners to offer safe and effective procedures while allowing patients to benefit from state-of-the-art, clinically proven technologies and treatments.

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, August 11, 2022 - 1:00pm
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nausea, Trial of the century, Female, SEC, Cancer, Clinical trial, Urine, Pain, Blood, Fever, Patient, Swelling, Skin, Clothing, Sodium bicarbonate, Perforation, Breast milk, Disease, Risk, NDA, Technology, Private Securities Litigation Reform Act, UTUC, Patient Information Advisory Group, Recurrence, Ureter, Safety, Water, Birth, Growth, Neoplasm, Man, Fatigue, NMIBC, Bladder cancer, Bone marrow, COVID-19, Stomach, Urinary bladder, Urination, Kidney, Time, Orphan drug, Transitional cell carcinoma, FDA, Vomiting, Abdomen, Nephrectomy, Company, Twitter, View, TURBT, Urinary tract infection, Transitional epithelium, Medicine, Adult, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Pharmakon—Danish College of Pharmacy Practice, Mitomycin C, Mitomycins

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005112/en/

Starlizard Integrity Services identifies 84 suspicious football matches played globally in first half of 2022

Retrieved on: 
Monday, August 8, 2022 - 3:23pm
Data analysis, SIS, Research, Sport, Nature, Football, Online gambling, Phosphorus

LONDON, Aug. 8, 2022 /PRNewswire/ -- New data from Starlizard Integrity Services (SIS) has revealed that 84 football matches played around the world between 1 January and 30 June 2022 were deemed "suspicious". Of these, 26 (31%) took place in the top-level domestic competitions of various countries.

Key Points: 
  • LONDON, Aug. 8, 2022 /PRNewswire/ -- New data from Starlizard Integrity Services (SIS) has revealed that 84 football matches played around the world between 1January and 30June 2022 were deemed "suspicious".
  • The 84 matches considered "suspicious" in the first half of 2022 represent 0.45% of a total of 18,845 football matches analysed by SIS during the period.
  • The SIS data also revealed that:
    The 84 suspicious matches were played in 30 different countries.
  • Starlizard Integrity Services (SIS) is the specialist integrity division of Starlizard, the London-based sports betting consultancy.

Starlizard Integrity Services identifies 84 suspicious football matches played globally in first half of 2022

Retrieved on: 
Monday, August 8, 2022 - 3:20pm
Data analysis, SIS, Research, Sport, Nature, Football, Online gambling, Phosphorus

LONDON, Aug. 8, 2022 /PRNewswire/ -- New data from Starlizard Integrity Services (SIS) has revealed that 84 football matches played around the world between 1 January and 30 June 2022 were deemed "suspicious". Of these, 26 (31%) took place in the top-level domestic competitions of various countries.

Key Points: 
  • LONDON, Aug. 8, 2022 /PRNewswire/ -- New data from Starlizard Integrity Services (SIS) has revealed that 84 football matches played around the world between 1January and 30June 2022 were deemed "suspicious".
  • The 84 matches considered "suspicious" in the first half of 2022 represent 0.45% of a total of 18,845 football matches analysed by SIS during the period.
  • The SIS data also revealed that:
    The 84 suspicious matches were played in 30 different countries.
  • Starlizard Integrity Services (SIS) is the specialist integrity division of Starlizard, the London-based sports betting consultancy.

WaterIQ Technologies™ Appoints Board of Directors to Drive Next Phase of Growth for Ultrasonic Algae and BioFilm Treatment Solutions

Retrieved on: 
Monday, August 8, 2022 - 3:00pm
Technology, Health, Other Energy, Utilities, Environmental Issues, Energy, Other Natural Resources, Environment, Research, Mining, Minerals, Software, Natural Resources, Science, Green Technology, Insituform, Principal, Drinking, CEO, Phosphorus, DHL, NYSE, Pond, Technology, Ladbrokes Coral, Ernst, Growth, Lake, Board, Drinking water, HOAS, Business, Recreation, O2 (brand), AG, Software as a service, Life, Founder, SAAS, Lupo, LLC, CDC, Sunak, Wharton School of the University of Pennsylvania, SAK, Industrial, Nitrogen, Water, CAGR, Worcester Polytechnic Institute, Industrial internet of things, Engineering, Board of directors, Nutrient, Harvard Business School, University, Moses Austin, Princeton University, Seattle University, Management, Thomas Lawrence (field hockey), Northeastern University

WaterIQ Technologies , the leader in next-generation ultrasonic solutions to combat harmful algae and biofilm without the use of chemicals, has announced world-renowned individuals to its Board of Directors.

Key Points: 
  • WaterIQ Technologies , the leader in next-generation ultrasonic solutions to combat harmful algae and biofilm without the use of chemicals, has announced world-renowned individuals to its Board of Directors.
  • Lawrence Field Mr. Field is CEO, and Chairman of the Board of WaterIQ Technologies and Founder of LDF Ventures, LLC.
  • WaterIQ Technologies provides non-chemical ultrasonic algae remediation solutions that eliminate most species of harmful algae from water bodies within one to two weeks without causing harm to other forms of life.
  • WaterIQ Technologies combines world-class go-to-market engagement, technical expertise, innovative technology, and business processes to sustainably address the worlds growing algae crisis.

Algae Market is estimated to Rise at a CAGR of 10.9% during the Forecast Period, notes TMR Study

Retrieved on: 
Monday, August 8, 2022 - 12:30pm
First Nations in Ontario, United Nations, Survival, Zinc, Vitamin, Carbon, Food and Agriculture Organization, Phosphorus, Mineral, Cosmetics, Microalgae, Research, Environment, Antioxidant, Organic acid, Food, Iron, CAGR, Dangerous, Nutrient, Protein, Animal, Magnesium, Health, Biodiversity, Aquaculture

Insights on the algae market project that the market will rise at a CAGR of 10.9% during the forecast period, from 2022 to 2031.

Key Points: 
  • Insights on the algae market project that the market will rise at a CAGR of 10.9% during the forecast period, from 2022 to 2031.
  • Rise in the acceptance of algae-based food productsand a growing popularity of vegan food are expected to emerge as trends in the algae market.
  • They are also employed in pig and poultry husbandry, which is expected to drive increasing demand for algae market.
  • Depending on volume, the Asia Pacific dominated the global algae market in 2021, holding a 59.1% of the market share.

The Root Brands Releases its 7th product Mitochondria Defense Shield with NAD

Retrieved on: 
Saturday, August 6, 2022 - 1:24am
MDS, Multimedia, Vitamin, Degenerative disease, K2, Phosphorus, Mitochondrion, Mineral, Vitamin K, Growth, NAD, Magnesium, Vitamin D, Absorption, Plant, Enzyme, DNA, Flavonoid, Reactive oxygen species, Vegetable, Bacteria, Ageing, Calcium, Eukaryote, Protein, Microdeletion syndrome, Quercetin, Disease

Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.

Key Points: 
  • Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.
  • Mitochondria are tiny double membrane-bound organelles found in almost every cell of all organisms except bacteria, they are known as "the powerhouse of the cell".
  • It enters the mitochondria in its oxidized form and protects mitochondria from oxidative injury.
  • Vitamin D is vital for regulating the absorption of calcium and phosphorus and facilitating normal immune system function.

RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing

Retrieved on: 
Thursday, August 4, 2022 - 10:06pm
FDA, U.S. Securities and Exchange Commission, Cardiovascular disease, Ptosis, Duane syndrome, Risk, Eye injury, Glycosidic bond, Industry, GLOBE, Aneurysm, Beta blocker, Focal neurologic signs, Growth, RVL, Orthostatic hypotension, Avista Capital Partners, Hypotension, Achievement, Security (finance), Annual report, Myasthenia gravis, Marketing, Patient, Stroke, Mark (given name), Company, First, Blepharoplasty, Eye, Awareness, Nature, Horner's syndrome, Blood pressure, Headache, Orbit, Hypertension, Xanthine oxidase inhibitor, Metabolism, Nasdaq, Terminology, Glaucoma, Ophthalmoparesis, Pharmaceutical industry, Phosphorus

BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that it has entered into arrangements to secure up to $68.9 million in committed financing through a combination of equity and non-dilutive committed debt financing. Total proceeds anticipated at closing amount to $43.9 million, comprised of $23.9 million in aggregate gross proceeds from the private placement of ordinary shares and, concurrently, $20.0 million in second tranche senior secured notes by amending the Company’s existing Note Purchase Agreement waiving certain conditions to the funding of such notes. The referenced amendment also provides a $25.0 million commitment for third tranche senior secured notes, subject to a minimum revenue target.

Key Points: 
  • This financing reflects our belief in the brand and meaningfully enhances our financial position as we build momentum with our expanding launch of UPNEEQ.
  • We launched into medical aesthetics six months ago with a core sales group that we attracted from around the industry.
  • This financing places us on the path to execute our multi-channel strategy and to continue to attract great people, said James JD Schaub, Chief Operating Officer of RVL.
  • RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults.